Prescient Therapeutics unveils highly effective CellPryme-M cell therapy technology

Prescient Therapeutics confirms its new technology to improve cell therapy CellPryme-M is ready for clinical testing.

Clinical Oncology Company Prescient Therapeutics (ASX: PTX) today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M that is designed to enhance cell therapies.

Developed by Prescient in collaboration with the world’s leading cancer research institute Peter MacCallum Cancer Center, CellPryme-M produces superior cells during the cell production process that are “less prone to depletion, allowing longer killing activity of cancer and are able to improve the traffic and penetration of tumors compared to the current generation of CAR-T cells.

According to Prescient, CellPryme-M CAR-T cells perform “significantly better” than conventional CAR-T cells in highly aggressive solid cancer models.

CellPryme-M has already been confirmed as ready for use in clinical trials, and Prescient said it plans to use the platform to improve the cells used in its OmniCAR breakthrough programs.

“It’s GMP [Good Manufacturing Practice] The class product can easily be included in any CAR-T production program to significantly increase the ability to kill T-cell cancer by distorting their phenotype to a less differentiated state, “said the senior vice president of research. of Prescient Dr. Rebecca Lim.

“CellPryme-M changes key signaling pathways in just 15 minutes, which means that users can incorporate CellPryme-M into their production process virtually without interruption, even if their production timeframes are only 24 to 48 hours.

The company will also seek to license CellPryme-M to other cell therapy companies to improve conventional CAR-T programs and enter into value-added collaborations with outsiders.

CellPryme-M platform

Prescient’s second cell therapy platform, CellPryme-M, produces cells with superior phenotypes by influencing gene expression in immune cells. The cellular phenotype determines the clinical anticancer responses.

Cells produced by the CellPryme-M process showed very favorable characteristics required by more effective cell therapies, including: 50% more central memory T cells (highly clinically relevant subtype); double proportion of CD4 + helper T cells (for synergy with effector T cells); significantly more chemokine receptors (important for tumor trafficking and penetrance); and greater genomic stability and DNA repair for enhanced self-renewal.

In a mouse model of highly aggressive breast cancer that is highly resistant to conventional CAR-T, CellPryme-M CAR-T cells nearly doubled tumor control compared to conventional CAR-T and “significantly improve survival.”

New business opportunity

Prescient Managing Director and CEO Stephen Yatomi-Clark said CellPryme-M opens up a whole new business opportunity to license the platform to other cell therapy companies.

“It requires minimal intervention in existing and emerging production processes and therefore represents a relatively low barrier to implementation.”

“This opens up real trade opportunities for Prescient to include CellPryme-M in third-party manufacturing processes,” he added.

Dr Lim also said he saw “huge potential” for CellPryme-M to benefit from third-party CAR-T programs that fight good resistance and tumor penetration with their CAR T cells.

“It is also exciting that these effects are likely to extend CellPryme-M to other modalities of cell therapy such as CAR-NK, TCR T cells, etc., as tumor persistence and penetration continue to be the key to tumor clearance.” she added.

Leave a Comment

Your email address will not be published.